Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia



Status:Terminated
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:18 - 40
Updated:4/21/2016
Start Date:May 2013
End Date:August 2014

Use our guide to learn which trials are right for you!

An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia

This study is designed in two parts. Part 1 will assess the safety and tolerability of
different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood
pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can
prolong pregnancy in women with pre-eclampsia.


Key Inclusion criteria:

- Written informed consent was obtained before any assessment was performed.

- Women at 18 to 40 years of age with a pregnancy 28 weeks (0 days) and 33 weeks (+4
days) gestational age. Gestational age was based on mother's last menstruation; if
last menstruation was unknown, an alternative method was used as applicable and was
documented in the (electronic) Case Report/Record Form [(e)CRF].

- Women with a diagnosis of pre-eclampsia or superimposed pre-eclampsia requiring
hospitalization. Pre-eclampsia was defined as new onset of hypertension (SBP ≥ 140 or
DBP ≥ 90 mmHg) or gestational hypertension accompanied by proteinuria (>= 0.3 g/24h)
after 20 weeks of gestation. Superimposed pre-eclampsia was defined as chronic
hypertension with new onset of proteinuria after 20 weeks of gestation.

- Reassuring fetal testing (cardiotocography and biophysical profile)

Key Exclusion criteria:

- Severe hypertension (SBP ≥ 160 mmHg or DBP ≥ 110 mmHg) and /or those receiving
anti-hypertensive treatment at time of randomization.

- Clinically relevant electrocardiogram (ECG) abnormalities at screening excluding
those abnormalities commonly seen in pregnancy according to the Investigator.

- Symptoms indicative of severe pre-eclampsia or HELLP syndrome (Hemolysis, Elevated
Liver enzymes, and Low Platelet count) for which immediate delivery of the baby may
be indicated. Symptoms include persistent CNS symptoms (severe headaches, visual
changes, altered mentation), persistent right upper quadrant or epigastric pain,
nausea or vomiting, severe thrombocytopenia (<100,000/mm3) and abnormal (> 2X upper
limit of normal) liver enzymes (alanine aminotransferase [ALT] or aspartate
aminotransferase [AST]).

- Eclampsia during current pregnancy, vaginal bleeding present at screening, abruptio
placentae, oligohydramnios

- Current diagnosis of a seizure disorder that requires chronic medication.

- Pre-gestational diabetes (Type 1 or Type 2) with or without diabetic retinopathy.
Diagnosis (previous or current) of gestational diabetes, regardless of treatment, was
allowed

- Known allergy to magnesium sulfate or steroids.

- Multifetal gestation, known major fetal anomaly, intrauterine growth restriction
(<5th percentile).
We found this trial at
5
sites
Galveston, Texas 77555
?
mi
from
Galveston, TX
Click here to add this to my saved trials
Lexington, Kentucky 40509
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Mobile, Alabama 36693
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Modena, MO 41100
?
mi
from
Modena,
Click here to add this to my saved trials